Cynthia (Zhengyun) Qi
M.B.A., Yale School of Management; B.A., psychology and statistics, Mount Holyoke College
Summary of Experience
Ms. Qi specializes in health economics and outcomes research (HEOR). She has led the design and implementation of cost-effectiveness and budget-impact models to inform pricing decisions on new pharmaceutical products, and assisted in the development of regulatory submissions to several health assessment agencies, including the National Institute for Health and Care Excellence (NICE) in the UK and the pan-Canadian Oncology Drug Review (pCODR). She has also conducted empirical comparative-effectiveness studies using large retrospective databases and medical chart reviews; performed network meta-analyses and indirect comparisons; and leveraged clinical trial data to address a variety of research objectives. Ms. Qi has conducted research on a broad range of diseases and conditions, including breast cancer, multiple myeloma, renal cell carcinoma, acute leukemia, lymphoma, chronic kidney disease, diabetes, and several rare diseases and autoimmune disorders. Her work has been presented at clinical and economic research conferences and published in various peer-reviewed journals.
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review
Curr Med Res Opin. 2014 Apr; 30(4):537-45
October 22, 2019